Azelaic acid : Potential as a general antitumoural agent

Medical Hypotheses

Volumn 52, Issue 3, 1999, Pages 221-226

  Breathnach, A S ^a,b  

^a ST THOMAS HOSPITAL   (United Kingdom)

^b NONE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; AZELAIC ACID; OXIDOREDUCTASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; BLADDER CARCINOMA; BREAST CARCINOMA; CANCER CELL CULTURE; CELL PROLIFERATION; CYTOTOXICITY; DNA SYNTHESIS; DRUG DELIVERY SYSTEM; ENZYME INHIBITION; HUMAN; INTRAARTERIAL DRUG ADMINISTRATION; INTRALYMPHATIC DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; LUNG CARCINOMA; MELANOMA; MELANOMA CELL; MOUSE; NONHUMAN; NUDE MOUSE; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RESPIRATORY CHAIN; REVIEW; SQUAMOUS CELL CARCINOMA; TOPICAL DRUG ADMINISTRATION; XENOGRAFT;

ANIMALIA; MUS MUSCULUS;

EID: 0033103489     PISSN: 03069877     EISSN: None     Source Type: Journal    
DOI: 10.1054/mehy.1997.0647     Document Type: Article

References (52)

1. Nazzaro-Porro M., Passi S., Zina G., Breathnach A. S., Bernengo M., Galagher S. Effect of azelaic acid on human malignant melanoma. Lancet 1980; 1: 1109-1111.
2. Nazzaro-Porro M., Passi S., Picardo M. et al. Beneficial effect of 15 per cent azelaic acid cream on acne vulgaris. Br J Dermatol 1983; 109: 45-48.
3. Graupe K., Cunliffe W. J., Gollnick H. P. M., Zaumseil R. P. Efficacy and safety of topical azelaic acid (20%) cream: An overview of results from European clinical trials and experimental reports. Cutis 1996; 57 1S: 20-35.
4. Nazzaro-Porro M., Passi S., Picardo M. et al. L'acido azelaico nella rosacea. G Ital Dermatol Venereol 1991; 126(Suppl 1): 7-10.
5. Carmichael A. J., Marks R., Graupe K. A. et al. Topical azelaic acid in the treatment of rosacea. J Dermatol Treat 1993; 4(Suppl 1): S 19-22.
6. Nazzaro-Porro M. The use of azelaic acid in hyperpigmentation. Rev Contemp Pharmacother 1993; 4: 415-423.
7. Breathnach A. S. Melanin hyperpigmentation of skin: Melasma, topical treatment with azelaic acid and other therapies. Cutis 1996; 57(Suppl 1): 36-45.
8. Mortensen P. B. Dicarboxylic acids and the lipid metabolism. Danish Med Boll 1984; 31: 121-145.
9. Nazzaro-Porro M., Passi S., Morpurgo G., Breathnach A. S. Identification of tyrosinase inhibitors in cultures of pytirosporum, and their melanocytotoxic effect. In: Klaus S. N. (ed). Pigment Cell, Vol 1, Basel: Karger, 1979; 234-243.
10. Schallreuter K. U., Wood J. M. Azelaic acid as a competitive inhibitor of thioredoxin reductase in melanoma cells. Cancer Letters 1987; 36: 297-305.
11. Galhaup I. Azelaic acid: Mode of action at cellular and subcellular levels. In: Breathnach A. S., Graupe K., Stingl G. (eds) Azelaic Acid: A New Therapeutic agent. Acta Derm Venereol Stockh 1989; 43 (Suppl): 75-82.
12. Passi S., Picardo M., Nazzaro-Porro M., Breathnach A. S. et al. Anti-mitochondrial effect of medium chain length (C8 to C13) dicarboxylic acids. Biochem Pharmacol 1984; 33: 103-108.
13. Stamatidas D., Bulteau-Portois M. C., Moszowicz I. Inhibition of 5-alpha reductase activity in human skin by zinc and azelaic acid. Br J Dermatol 1988; 118: 627-632.
14. Bargoni N., Tazartes O. On the effect of aliphatic saturated dicarboxylic acids on anaerobic glycolysis in chicken embryo. Ital J Biochem 1983; 32: 385-390.
15. Passi S., Picardo M., De Luca C. et al. Scavenging activity of azelaic acid on hydroxyl radicals in vitro. Free Rad Res Comm 1991; 11: 329-339.
16. Passi S., Picardo M., Zompetta C. et al. Oxyradicals scavenging activity of azelaic acid in biological systems. Free Rad Res Comm 1991; 15: 17-28.
17. Akamatsu H., Miyachi Y., Komura J. Effect of azelaic acid on neutrophil function: A possible cause for its efficacy in treating pathogenetically unrelated diseases. Arch Dermatol Res 1991; 23: 1162-1166.
18. Mingrone G., Greco A. V., Nazzaro-Porro M., Passi S. Toxicity of azelaic acid. Drugs Clin Exp Res 1983; 9: 447-455.
19. Töpert M., Rach P., Siegmund F. Pharmacology and toxicology of azelaic acid. In: Breathnach A. S., Graupe K., Stingl G. (eds) Azelaic acid: a new therapeutic agent. Acta Dermatol Venereol (Stockh) 1989; (Suppl) 43: 14-19.
20. Passi S. Pharmacology and pharmacokinetics of azelaic acid. Rev Contemp Pharmacother 1993; 4: 441-447.
21. Pattarino F., Carlotti M. F., Gasco M. R. Topical delivery systems for azelaic acid: Effect of the suspended drug in microemulsion. Pharmazie 1944; 49: 72-73.
22. Bertuzzi A., Gandolfi A., Salinari S. Pharmacokinetic analysis of azelaic acid disodium salt. A proposed substrate for total parenteral nutrition. Clinic Pharmackinet 1991; 20: 411-419.
23. Tacchino R. M., Mingrone G., Marino F. et al. Short-term infusion of azelaic acid vs intralipid in healthy subjects evaluated by indirect calorimity. J Parent Ent Nut 1990; 14: 169-172.
24. Passi S., Nazzaro-Porro M., Picardo M. et al. Metabolism of straight saturated medium chain length (C9 to C12) dicarboxylic acids. J Lipid Res 1983; 34: 1140-1147.
25. Breathnach A. S., Martin B., Nazzaro-Porro M., Passi S., Mann Cooper J., Morpurgo G. Effects of dicarboxylic acids on normal human melanocytes in dispersed tissue culture. Br J Dermatol 1979; 101: 641-649.
26. Lemic-Stojcevic L., Nias A. H. W., Breathnach A. S. Effect of azelaic acid on melanoma cells in culture. Exp Dermatol 1944; 4: 78-81.
27. Zaffaroni N., Villa R., Silvestro L. et al. Cytotoxic activity of azelaic acid against human primary melanoma cultures and established cell lines. Anti Can Res 1990; 10: 1599-1602.
28. 9) on human choroidal melanoma in cell culture. Invest Ophthal Vis Sci 1989; 30: 491-498.
29. Robins E. J., Breathnach A. S., Ward B. J. et al. Effect of dicarboxylic acids on Harding-Passey and Cloudman S91 melanoma cells in tissue culture. J Invest Dermatol 1985; 85: 216-221.
30. Hu F., Mah K., Teramura J. D. Effect of dicarboxylic acids on normal and malignant melanocytes in tissue culture. Br J Dermatol 1989; 101: 17-26.
31. 9) on a human squamous carcinoma line in culture. Histol Histopathol 1989; 4: 167-171.
32. Picardo M., Passi S., Sirianni M. C., Fiorilli M., Russo G. D., Cortesi E. et al. Activity of azelaic acid on cultures of lymphoma and leukemia-derived cell lines, normal resting and stimulated lymphocytes and 3T3 fibroblasts. Biochem Pharm 1985; 34: 1653-1665.
33. Geier G., Hauschild T., Bauer R. et al. Der einfluss von azelainsaure auf das wachstum von melanomazellkulturen im vergleich zu fibroblastenkulturen. Hautartz 1986; 37: 146-148.
34. Breathnach A. S., Martin B., Nazzaro-Porro M. et al. Effects of dicarboxylic acids on normal human melanocytes in dispersed tissue culture. Br J Dermatol 1979; 101: 641-649.
35. Grammatico P., Scarpa S., Picardo M. et al. Karyotype modifications in human malignant melanoma cell cultures after treatment with azelaic acid. Mut Res 1993; 300: 119-123.
36. Mensing H., Remier C., Schmidt K. U. Chemotactic behaviour of melanoma cells in vitro: Correlation with plasminogen activator activity and influence of azelaic acid activity. J Invest Dermatol 1984; 84: 445.
37. Addo-Boadu K., Wojta J., Christ G. et al. Azelaic acid decreases the fibrinolytic potential of cultured melanoma cells in vitro. Cancer Letters 1996; 103: 125-129.
38. Binder B. R. Influence of urokinase on cell proliferation and invasion. Blood Coag Fibrinol 1990; 1: 717-720,
39. Reith R. W., Williamson J. D., Breathnach A. S. et al. Inhibition of vaccinia virus replication by azelaic acid. IRCS Med Sci 1985; 13: 783-784.
40. Bojar R. A., Holland K. T. Azelaic acid: A review of its antimicrobial activities. Rev Contemp Pharmacother 1993; 4: 303-414.
41. 3H) thymidine labelling index, and mitotic index as compared with tumour growth and tumour weight in zenotransplanted melanoma. Changes due to local and systemic application of azelaic acid. In: Breathnach A. S., Graupe K., Stingl G. (eds) Azelaic acid a new therapeutic agent. Acta Dermato-venereol Stockh 1989; 143(Suppl): 67-74.
42. Leibl H., Stingl G., Pehamberger H. et al. Inhibition of DNA synthesis of melanoma cells by azelaic acid. J Invest Dermatol 1985; 85: 417-422.
43. Nazarro-Porro M., Passi S., Balus L., Breathnach A. S. Effects of dicarboxylic acids on lentigo maligna. J Invest Dermatol 1979; 72: 296-305.
44. Nazzaro-Porro M., Passi S., Zina G. et al. Ten years experience of treating lentigo maligna with topical azelaic acid. In: Breathnach A. S., Graupe K., Stingl G. (eds) Azelaic acid a new therapeutic agent. Acta Derm Venereol Stockh 1989; 143: (Suppl): 49-57.
45. Nazzaro-Porro M., Zina G., Breathnach A. S. et al. Case reports: Azelaic acid therapy for palpebral lesions of lentigo maligna (melanoma in situ) and for melanoma in situ progressed to invasive melanoma. G Ital Dermatol Venereol 1998; 133: 79-85.
46. Breathnach A. S., Nazzaro-Porro M., Passi S., Zina G. Azelaic acid therapy in disorders of pigmentation. Clin Dermatol 1989: 7: 106-119.
47. Nazzaro-Porro M., Breathnach A. S., Balus L. et al. A case of recurrent (following surgery × 2) invasive malignant melanoma with satellitosis (stage IIIA) successfully resolving after azelaic acid treatment administered by several routes. Clin Exper Dermatol 1996; 21: 320-324.
48. Rodriguez P., Lopez P. M. Treatment of lentigo maligna with azelaic acid. Int J Dermatol 1993; 32: 363-364.
49. Lanthaler M., Stoltz W., Braun-falco. Lentigo der glans penis. Hautartz 1989; 40: 222-225.
50. Kamayema K., Morita M., Sugaya K. Treatment of reticulate acropigmentation of Kitamura with azelaic acid. An immunochemical and electron microscopic study. J Am Acad Dermatol 1992; 26: 817-820.
51. Fitzpatrick T. B. Editorial comment: Pigmentary disorders. In: Sober A. J., Fitzpatrick T. B. (eds) The Yearbook Of Dermatology 1987. Chicago, Year Book Medical Publishers: 313-314.
52. U-Taniguchi Y., Futuke K., Matsutani H. et al. Cell cycle inhibition of HTLV-1 transformed T cell lines by retinoic acid: The possible therapeutic use of thioredoxin reductase inhibitors. Oncology Research 1995; 7(3-4): 183-189.